Articles related to Internal Medicine

The FDA has required that Amgen compare its approved KRAS-targeted therapy sotorasib (Lumakras) 960-mg dose with a 240-mg dose as one of its accelerated approval post-marketing requirements, a paradigm-shifting event that signals new scrutiny around determining the labeled dose for targeted oncology drugs, which still follow outdated maximum tolerated dose (MTD) principles in cytotoxic agents.

This BMJ editorial examines whether approaches better equipped to compare rates of menstrual variation in vaccinated versus unvaccinated populations are needed, based on the reports of changes to periods and unexpected vaginal bleeding after vaccination. The US has taken the first step, earmarking $1.67M from the National Institutes of Health to encourage research.

Publication: JAMA Oncology Design: An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.

Review Publication: Hematology AdvisorDesign: At the Annual Meeting of the Society of Hematologic Oncology, researchers presented a study identifying a higher percentage of patients with germline predisposition syndromes (GPS).Results: Following a review of medical records of patients diagnosed with GPS between 1994 and 2018, the investigators reported that the detection of GPS positively impacted medical care in 91% of cases, including proper selection of a bone marrow donor, selection of drug and conditioning regimens, and genetic counseling.

ReachMD offers this CME/video case study on Duchenne Muscular Dystrophy (DMD), new genetic understandings, MET inhibitor use, and presentation with extra muscular manifestations. The program also highlights the challenges healthcare professionals face when it comes to diagnosing this complex condition.

Antibodies against COVID-19 continue to perplex and confound physicians and research scientists. Although people who have gotten COVID-19 or been vaccinated against the respiratory disease develop a humoral immune response that protects them from reinfection, those antibodies decline over time, leaving people vulnerable to reinfection. Understanding why this happens is critically important to modeling how COVID-19 spreads through the general population, including children.